<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04535895</url>
  </required_header>
  <id_info>
    <org_study_id>1094/2020</org_study_id>
    <nct_id>NCT04535895</nct_id>
  </id_info>
  <brief_title>Simultaneous Integrated Boost Technique in Breast Cancer Radiotherapy</brief_title>
  <official_title>Simultaneous Integrated Boost (SIB) Technique in the Adjuvant Radiotherapy of Breast Cancer Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adjuvant radiotherapy after breast conserving surgery has been shown to improve both local&#xD;
      control and overall survival. Dose escalation of the tumor bed by addition of a boost after&#xD;
      whole breast radiotherapy reduces the risk of local recurrence in invasive breast cancer.&#xD;
&#xD;
      Simultaneous integrated boost (SIB) techniques have been shown to provide more conformal&#xD;
      treatment plans than conventional sequential boost, in addition, SIB enables a reduction in&#xD;
      the overall treatment time by 1 week compared to conventional boost techniques.&#xD;
&#xD;
      The proposed study is aimed at evaluating radiation-induced toxicity in patients treated with&#xD;
      breast-conserving surgery in combination with radiotherapy using SIB technique.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Radiation induced toxicity (grade 2 or higher)</measure>
    <time_frame>Measurement at the last 1 day of radiotherapy</time_frame>
    <description>Toxicity score using Common Terminology for Adverse Events (CTCAE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute Radiation induced toxicity (grade 2 or higher)</measure>
    <time_frame>Measurement 3 months after completion of radiotherapy</time_frame>
    <description>Toxicity score using Common Terminology for Adverse Events (CTCAE)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Radiotherapy Side Effect</condition>
  <arm_group>
    <arm_group_label>Simultaneous integrated boost arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Simultaneous integrated boost</intervention_name>
    <description>Adjuvant breast cancer irradiation including simultaneous integrated boost</description>
    <arm_group_label>Simultaneous integrated boost arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Invasive breast cancer or ductal carcinoma in situ&#xD;
&#xD;
          -  Breast conserving surgery&#xD;
&#xD;
          -  Complete tumor resection&#xD;
&#xD;
          -  Treatment with adjuvant radiotherapy of the breast&#xD;
&#xD;
          -  Indication for boost Irradiation&#xD;
&#xD;
          -  Given informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Incomplete tumor resection&#xD;
&#xD;
          -  Mastectomy&#xD;
&#xD;
          -  Distant metastases at diagnosis&#xD;
&#xD;
          -  Unable to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanja Langsenlehner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz, Dept. of Therapeutic Radiology and Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tanja Langsenlehner, MD</last_name>
    <phone>0043 316 385 87869</phone>
    <email>tanja.langsenlehner@medunigraz.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanja Langsenlehner, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>Hurkmans CW, Dijckmans I, Reijnen M, van der Leer J, van Vliet-Vroegindeweij C, van der Sangen M. Adaptive radiation therapy for breast IMRT-simultaneously integrated boost: three-year clinical experience. Radiother Oncol. 2012 May;103(2):183-7. doi: 10.1016/j.radonc.2011.12.014. Epub 2012 Jan 24.</citation>
    <PMID>22280808</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>September 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2020</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

